Avenge Bio

Avenge Bio was founded by an experienced team of proven biotech executives to develop transformative therapeutics which can potentially eradicate intractable solid tumors. Avenge Bio is developing our proprietary, allogeneic LOCOcyteTM platform for precision delivery of cytokines and other highly potent immunomodulatory molecules for a controlled period of time. Through this approach we are able to generate robust, local and systemic anti-tumor immune responses, without the toxicities associated with traditional immunotherapies. The LOCOcyteTM platform was developed from extensive research and experience of Dr. Omid Veiseh at Rice University and supported by Longitude Capital, CAM Capital, Perceptive Xontogeny, Rock Springs, Pappas Capital, and other leading healthcare investors. Together we are using the strength and efficiency of our platform to create a broad pipeline of therapeutics that target a wide range of difficult to treat solid tumors.

avengebio (@AvengeBio) / X

Michael Heffernan on LinkedIn: I am excited to announce the closing of Avenge Bio's $45 million Series A…

Avenge Bio Appoints Douglas Carlson as Chief Operating and Financial Officer

Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors

BioCentriq Announces Successful Tech Transfer From Avenge Bio for Manufacturing of Drug Product AVB-001 Resulting in Dosing of First Patient in Phase 1/2 Clinical Trial

Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors

DelveInsight Business Research LLP on LinkedIn: Pharma News Updates for AbbVie, Novartis, Avenge Bio, Eli Lilly

Stanley Tam email address & phone number Avenge Bio Corporate Controller contact information - RocketReach

Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors